Log in

NASDAQ:GEMPGemphire Therapeutics Stock Price, Forecast & News

-0.15 (-2.29 %)
(As of 07/14/2020)
Today's Range
Now: $6.41
50-Day Range
MA: $8.53
52-Week Range
Now: $6.41
Volume39,841 shs
Average Volume116,318 shs
Market Capitalization$95.32 million
P/E RatioN/A
Dividend YieldN/A
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.
Read More
Gemphire Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GEMP



Sales & Book Value

Annual SalesN/A
Book Value$0.54 per share


Net Income$-23,640,000.00


Market Cap$95.32 million
Next Earnings DateN/A
-0.15 (-2.29 %)
(As of 07/14/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive GEMP News and Ratings via Email

Sign-up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions

How has Gemphire Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Gemphire Therapeutics' stock was trading at $14.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GEMP stock has decreased by 55.8% and is now trading at $6.41.
View which stocks have been most impacted by Coronavirus

How were Gemphire Therapeutics' earnings last quarter?

Gemphire Therapeutics Inc (NASDAQ:GEMP) announced its quarterly earnings data on Friday, March, 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.15.
View Gemphire Therapeutics' earnings history

Has Gemphire Therapeutics been receiving favorable news coverage?

Headlines about GEMP stock have been trending negative on Monday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Gemphire Therapeutics earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Gemphire Therapeutics

Who are some of Gemphire Therapeutics' key competitors?

What other stocks do shareholders of Gemphire Therapeutics own?

Who are Gemphire Therapeutics' key executives?

Gemphire Therapeutics' management team includes the following people:
  • Dr. Charles L. Bisgaier, Co-Founder, Chairman & Chief Scientific Officer (Age 65)
  • Dr. Steven R. Gullans, CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer (Age 66)
  • Mr. Seth Reno, Chief Commercial Officer (Age 52)
  • Mr. Jeffrey S. Mathiesen C.P.A., CPA, Consultant (Age 58)
  • Ms. Amy Zaremba Rabourn, Director of Fin.

When did Gemphire Therapeutics IPO?

(GEMP) raised $30 million in an IPO on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

What is Gemphire Therapeutics' stock symbol?

Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."

How do I buy shares of Gemphire Therapeutics?

Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gemphire Therapeutics' stock price today?

One share of GEMP stock can currently be purchased for approximately $6.41.

How big of a company is Gemphire Therapeutics?

Gemphire Therapeutics has a market capitalization of $95.32 million. Gemphire Therapeutics employs 9 workers across the globe.

What is Gemphire Therapeutics' official website?

The official website for Gemphire Therapeutics is www.gemphire.com.

How can I contact Gemphire Therapeutics?

Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.